(MCOV-B) Medicover (publ) - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0009778848
MCOV-B: Healthcare services, Diagnostic services, Medical tests
Medicover AB (publ) is a well-established player in the healthcare and diagnostics industry, operating primarily in Poland, Sweden, and select international markets. Founded in 1995 and headquartered in Stockholm, the company has built a robust platform that integrates outpatient and inpatient care, dental services, and a range of preventive care offerings. What makes Medicover unique is its ability to bundle non-medical services—such as sports memberships, benefit cards, and wellness programs—into its healthcare ecosystem, creating a one-stop solution for its customers. This diversification not only enhances patient stickiness but also provides a steady revenue stream.
On the diagnostics front, Medicover offers an extensive menu of tests spanning allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry, and advanced areas like human genetics and molecular biology. This comprehensive diagnostic capability is a critical differentiator, enabling the company to provide accurate and timely results that are essential for both clinical decision-making and personalized medicine. By serving corporate clients, individuals, and public payers, Medicover has positioned itself as a trusted partner across the healthcare value chain.
From a financial perspective, Medicover AB (publ) is a large-cap company with a market capitalization of 26,754.77M SEK. Its trailing P/E ratio of 118.01 reflects a premium valuation, likely driven by its strong market position and growth prospects. The forward P/E of 64.94 suggests that investors expect the company to deliver on its growth initiatives. With a P/B ratio of 5.61, the market is assigning a significant premium to the companys book value, indicating confidence in its intangible assets and future earnings potential. The P/S ratio of 15.89 highlights the scalability of its business model, particularly in a sector where high margins are less common.
For investors and fund managers, Medicover represents an interesting case study of a healthcare company that has successfully scaled its operations while maintaining profitability. Its integrated healthcare and diagnostics model provides a moat against competitors, while its diversification into non-medical services adds resilience to its revenue streams. However, the high valuation multiples warrant close scrutiny, as they imply high expectations for future performance. Understanding the interplay between its operational efficiency, regulatory environment, and market expansion strategies will be key to assessing its long-term investment potential.
Medicover AB (publ) trades under the ticker symbol MCOV-B on the Stockholm Stock Exchange, classified under the Health Care Services sub-industry within the GICS framework. For more information, investors can visit the company’s website at https
Additional Sources for MCOV-B Stock
MCOV-B Stock Overview
Market Cap in USD | 2,619m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception |
MCOV-B Stock Ratings
Growth 5y | 45.4% |
Fundamental | 10.4% |
Dividend | 56.1% |
Rel. Strength Industry | 37.5 |
Analysts | - |
Fair Price Momentum | 187.16 SEK |
Fair Price DCF | 34.41 SEK |
MCOV-B Dividends
Dividend Yield 12m | 0.70% |
Yield on Cost 5y | 1.58% |
Annual Growth 5y | 14.43% |
Payout Consistency | 98.0% |
MCOV-B Growth Ratios
Growth Correlation 3m | 66% |
Growth Correlation 12m | 46.7% |
Growth Correlation 5y | 19.9% |
CAGR 5y | 17.84% |
CAGR/Max DD 5y | 0.26 |
Sharpe Ratio 12m | -0.47 |
Alpha | 28.89 |
Beta | 0.81 |
Volatility | 41.91% |
Current Volume | 31.9k |
Average Volume 20d | 53.8k |
As of March 15, 2025, the stock is trading at SEK 194.00 with a total of 31,910 shares traded.
Over the past week, the price has changed by -8.06%, over one month by -6.28%, over three months by +5.66% and over the past year by +38.67%.
Neither. Based on ValueRay Fundamental Analyses, Medicover (publ) is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 10.35 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MCOV-B as of March 2025 is 187.16. This means that MCOV-B is currently overvalued and has a potential downside of -3.53%.
Medicover (publ) has no consensus analysts rating.
According to ValueRays Forecast Model, MCOV-B Medicover (publ) will be worth about 207.8 in March 2026. The stock is currently trading at 194.00. This means that the stock has a potential upside of +7.09%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 223.5 | 15.2% |
Analysts Target Price | - | - |
ValueRay Target Price | 207.8 | 7.1% |